Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors - Robert L. Wilensky, MD

↳ This is a section part of Moment: CRT 2015 Atherosclerosis & Research - Atherosclerosis & Lipid Management

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$20.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors presented by Robert L. Wilensky, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$20.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows
Physiology technicians
Nurses and other allied healthcare professionals
Imaging Specialists
Radiologists

Session Name: Atherosclerosis & Lipid Management

Track: Atherosclerosis & Research

Learning Objectives

The latest updates in Atherosclerosis & Research

Other Components in this Moment

Optimization of Lipid Parameters - Evan A. Stein, MD, PhD

Update on HDL Infusions and Atherosclerosis Regression in the ACS Patient - H. Bryan Brewer Jr., MD

Ezetimibe: From Drug Development to IMPROVIT - Harry R Davis Jr., PhD

Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors - Robert L. Wilensky, MD

Prospects for CV Risk Factor Reduction with PCSK9 and CEPT Inhibitor Therapies - A. Michael Lincoff, MD

Update on the Role of PCSK9 in the Treatment of the High-Risk CVD Patient - Evan A. Stein, MD, PhD

LDL Reduction By PCSK9 Inhibition / Alirocumab - Dean J Kereiakes, MD

Are Triglycerides a Biomarker or Risk Factor in CVD? - Allen J. Taylor, MD

Is HDL a Biomarker or Risk Factor for CVD? - H. Bryan Brewer Jr., MD

Update on Clinical Trials with Novel CETP Inhibitors to Raise HDL: Where Are We Today? - H. Bryan Brewer Jr., MD

Loading Simple Education